Trial ID or NCT#

NCT00379145

Status

not recruiting iconNOT RECRUITING

Purpose

RATIONALE: Drugs used in chemotherapy, such as trabectedin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well trabectedin works in treating patients with advanced, persistent, or recurrent leiomyosarcoma of the uterus.

Official Title

A Phase II Evaluation of Trabectedin (Yondelis, R279741) in the Treatment of Advanced, Persistent, or Recurrent Uterine Leiomyosarcomas

Eligibility Criteria

Ages Eligible for Study: 18 Years to 120 Years
Sexes Eligible for Study: Female
Accepts Healthy Volunteers: No

Investigator(s)

Nelson Teng
Jonathan S. Berek, MD, MMSc
Jonathan S. Berek, MD, MMSc
Gynecologic oncologist
Laurie Kraus Lacob Professor

Contact us to find out if this trial is right for you.

CONTACT

Maureen Sutton
(650) 725-9167